Enrica Alteri is currently a member of the Scientific Committee and faculty of the Master in Drug Research and Development (R&D) of the University of Geneva, and has been a consultant for Swissmedic.

Enrica gives university lectures on various regulatory aspects of R&D. She is member of the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII (Real World Data/Real World Evidence), and the CIOMS Working Group Education. Most recently, she has been appointed as a Core Member of the Proposal Review Committee of Unitaid, and as a member of the World Health Organization (WHO) Technical Advisory Group, WHO-listed Authorities.

In 2012, Enrica joined the European Medicines Agency, where she worked as Head of the Human Medicines Evaluation Division, and later as Head of the Human Medicines R&D Support Division. She was a member of the Executive Board until 2020. In these roles, she was part of many high impact initiatives (e.g., transparency of clinical trial data, development of regulatory science strategy to 2025).

Before that, Enrica spent 13 years at Ciba-Geigy/Novartis, involved in major projects that yielded Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS. She led the Pharmacovigilance and Risk Management team at Serono for 14 years.

Enrica is an MD, with post-doctoral training at the National Cancer Institute in the USA and a diploma in Pharmaceutical Medicine.